{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "dollar-amount", "type": "definition", "offset": [19, 32]}, {"key": "to-pay", "type": "clause", "offset": [49, 55]}, {"key": "the-application", "type": "clause", "offset": [74, 89]}, {"key": "income-statement", "type": "definition", "offset": [140, 156]}, {"key": "in-accordance-with", "type": "clause", "offset": [157, 175]}, {"key": "generally-accepted-accounting-principles", "type": "definition", "offset": [176, 216]}, {"key": "exhibit-d", "type": "clause", "offset": [234, 243]}], "size": 3, "samples": [{"hash": "3y2dihpQwXJ", "uri": "/contracts/3y2dihpQwXJ#royalty-amount", "label": "Value Added Reseller License Agreement (Esps Inc)", "score": 18.0, "published": true}, {"hash": "3wRsrzGIyZd", "uri": "/contracts/3wRsrzGIyZd#royalty-amount", "label": "Value Added Reseller License Agreement (Esps Inc)", "score": 18.0, "published": true}, {"hash": "2Qz0MLC8isd", "uri": "/contracts/2Qz0MLC8isd#royalty-amount", "label": "Value Added Reseller License Agreement (Esps Inc)", "score": 18.0, "published": true}], "snippet": "means the absolute dollar amount that VAR agrees to pay Versant each time the Application is distributed and recognized as revenue on VAR's income statement in accordance with Generally Accepted Accounting Principles, as set forth in Exhibit D hereto.", "hash": "d1887c2fc9bcd5f0df8b2579566ad06b", "id": 1}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [36, 52]}, {"key": "in-the-territory", "type": "clause", "offset": [71, 87]}, {"key": "actual-amount", "type": "definition", "offset": [93, 106]}, {"key": "section-63", "type": "clause", "offset": [179, 190]}], "size": 3, "samples": [{"hash": "kLfzcoNV6Sw", "uri": "/contracts/kLfzcoNV6Sw#royalty-amount", "label": "License and Api Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "avlPTbnXz3R", "uri": "/contracts/avlPTbnXz3R#royalty-amount", "label": "License and Api Supply Agreement (Cara Therapeutics, Inc.)", "score": 24.8521556854, "published": true}, {"hash": "b9thJ0UkhiN", "uri": "http://ir.caratherapeutics.com/static-files/8ff3a540-1062-498f-9220-d5f627ab086f", "label": "ir.caratherapeutics.com", "score": 8.1704311371, "published": false}], "snippet": "means, with respect to a particular Licensed Product sold commercially in the Territory, the actual amount (in Dollars) payable by CKD to Cara as royalty on such sale pursuant to Section 6.3.", "hash": "082bd6f50009fe29f2cdf4b3774365f5", "id": 2}, {"snippet_links": [{"key": "calendar-quarter", "type": "clause", "offset": [15, 31]}, {"key": "sum-of", "type": "clause", "offset": [36, 42]}, {"key": "product-revenues", "type": "definition", "offset": [65, 81]}, {"key": "in-the-united-states", "type": "clause", "offset": [82, 102]}, {"key": "five-percent", "type": "clause", "offset": [104, 116]}, {"key": "in-the-territory", "type": "clause", "offset": [142, 158]}, {"key": "outside-the-united-states", "type": "definition", "offset": [159, 184]}, {"key": "in-the-event", "type": "clause", "offset": [255, 267]}, {"key": "units-issued", "type": "clause", "offset": [444, 456]}], "size": 2, "samples": [{"hash": "gjzwMYsT8QH", "uri": "/contracts/gjzwMYsT8QH#royalty-amount", "label": "Purchase Agreement (Icos Corp / De)", "score": 18.0, "published": true}, {"hash": "2GUeAhNoExL", "uri": "/contracts/2GUeAhNoExL#royalty-amount", "label": "Product Development Agreement (Icos Corp / De)", "score": 18.0, "published": true}], "snippet": "means for each calendar quarter the sum of seven percent (7%) of Product Revenues in the United States, five percent (5%) of Product Revenues in the Territory outside the United States and [ * ] in the Territory for such calendar quarter; provided, that, in the event that less than 700 Units are issued, such seven percent (7%) and five percent (5%) shall be adjusted by multiplying each by a fraction, the numerator of which is the number of Units issued and the denominator of which is 700.", "hash": "8d34b617e75a9b8b92800f94354d1245", "id": 3}, {"snippet_links": [], "size": 2, "samples": [{"hash": "iEDTk5UP5bE", "uri": "/contracts/iEDTk5UP5bE#royalty-amount", "label": "Asset Purchase Agreement (Neoprobe Corp)", "score": 21.3990421295, "published": true}, {"hash": "i3fOioAQe77", "uri": "/contracts/i3fOioAQe77#royalty-amount", "label": "Asset Purchase Agreement (Neoprobe Corp)", "score": 20.5441474915, "published": true}], "snippet": "has the meaning set forth in Section 2.9(a).", "hash": "ad4c1143e664c1910adf1950222d5ee0", "id": 4}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-product", "type": "definition", "offset": [36, 52]}, {"key": "in-the-territory", "type": "clause", "offset": [71, 87]}, {"key": "actual-amount", "type": "definition", "offset": [93, 106]}, {"key": "japanese-yen", "type": "definition", "offset": [111, 123]}, {"key": "section-63", "type": "clause", "offset": [190, 201]}], "size": 2, "samples": [{"hash": "duFQF6fZKuH", "uri": "/contracts/duFQF6fZKuH#royalty-amount", "label": "License Agreement (Cara Therapeutics, Inc.)", "score": 24.8521556854, "published": true}, {"hash": "b9thJ0UkhiN", "uri": "http://ir.caratherapeutics.com/static-files/8ff3a540-1062-498f-9220-d5f627ab086f", "label": "ir.caratherapeutics.com", "score": 8.1704311371, "published": false}], "snippet": "means, with respect to a particular Licensed Product sold commercially in the Territory, the actual amount (in Japanese Yen ) payable by Maruishi to Cara as royalty on such sale pursuant to Section 6.3.", "hash": "59be404e89cc77d043d1a28449486137", "id": 5}, {"snippet_links": [{"key": "during-the-term", "type": "clause", "offset": [33, 48]}, {"key": "april-1", "type": "definition", "offset": [55, 62]}, {"key": "through-december", "type": "clause", "offset": [69, 85]}, {"key": "the-royalty", "type": "clause", "offset": [96, 107]}, {"key": "net-sales-of-licensed-products", "type": "definition", "offset": [152, 182]}, {"key": "by-licensee", "type": "clause", "offset": [310, 321]}, {"key": "contract-year", "type": "definition", "offset": [329, 342]}, {"key": "products-sold", "type": "clause", "offset": [463, 476]}, {"key": "royalty-amounts", "type": "clause", "offset": [654, 669]}, {"key": "quarterly-period", "type": "definition", "offset": [829, 845]}, {"key": "licensee-will", "type": "clause", "offset": [888, 901]}, {"key": "the-net", "type": "clause", "offset": [912, 919]}, {"key": "calculate-the", "type": "clause", "offset": [957, 970]}, {"key": "the-foreign-currency", "type": "definition", "offset": [989, 1009]}, {"key": "rate-published", "type": "clause", "offset": [1066, 1080]}, {"key": "the-us", "type": "clause", "offset": [1084, 1091]}, {"key": "wall-street", "type": "definition", "offset": [1093, 1104]}, {"key": "day-of", "type": "clause", "offset": [1134, 1140]}, {"key": "calendar-quarter", "type": "clause", "offset": [1145, 1161]}, {"key": "quarterly-reporting-period", "type": "definition", "offset": [1170, 1196]}, {"key": "after-january", "type": "clause", "offset": [1205, 1218]}, {"key": "covered-by", "type": "definition", "offset": [1329, 1339]}, {"key": "claims-of", "type": "clause", "offset": [1344, 1353]}, {"key": "issued-in", "type": "definition", "offset": [1373, 1382]}, {"key": "the-sale", "type": "clause", "offset": [1403, 1411]}, {"key": "issued-patent", "type": "definition", "offset": [1512, 1525]}, {"key": "not-covered", "type": "clause", "offset": [1727, 1738]}, {"key": "no-royalty", "type": "clause", "offset": [1797, 1807]}, {"key": "distribution-of", "type": "clause", "offset": [1844, 1859]}, {"key": "license-agreement", "type": "definition", "offset": [1888, 1905]}, {"key": "in-effect", "type": "clause", "offset": [1919, 1928]}, {"key": "patent-applications", "type": "definition", "offset": [1956, 1975]}, {"key": "no-patents", "type": "clause", "offset": [2073, 2083]}, {"key": "the-agreement", "type": "clause", "offset": [2154, 2167]}, {"key": "licensee-shall", "type": "clause", "offset": [2189, 2203]}, {"key": "to-licensor", "type": "definition", "offset": [2239, 2250]}, {"key": "other-restrictions", "type": "clause", "offset": [2255, 2273]}, {"key": "entitlement-to", "type": "clause", "offset": [2423, 2437]}, {"key": "compensation-for", "type": "clause", "offset": [2463, 2479]}, {"key": "the-issuance", "type": "clause", "offset": [2673, 2685]}, {"key": "sale-of", "type": "clause", "offset": [2752, 2759]}], "size": 1, "samples": [{"hash": "h1d3cdTzTge", "uri": "/contracts/h1d3cdTzTge#royalty-amount", "label": "License Agreement (Carbite Golf Inc)", "score": 18.0, "published": true}], "snippet": "shall have the following meaning during the Term: From April 1, 2001 through December 31, 2003, the Royalty Amount shall be: (A) ****% (****percent) of Net Sales of Licensed Products, for any Net Sales up to the first one million dozen Licensed Products (i.e., twelve million Licensed Product golf balls) sold by Licensee in the Contract Year, or (B) ***% (**** percent) of Net Sales of Licensed Products, on any Net Sales in excess of one million dozen Licensed Products sold by Licensee in the Contract Year; provided, that the Royalty Amount in preceding clauses (A) and (B) shall be capped at $**** (**** cents, U.S.) per dozen of Licensed Products. Royalty Amounts shall be paid in U.S. dollars. Royalty Amounts on Net Sales made in currencies other than U.S. dollars shall be converted to U.S. dollars as follows: for each quarterly period for reporting and paying Royalty Amounts, Licensee will determine the Net Sales made in each foreign currency, calculate the Royalty Amount in the foreign currency, and then convert to U.S. dollars by using the exchange rate published in the U.S. Wall Street Journal on the last business day of the calendar quarter in that quarterly reporting period. On and after January 1, 2004 during the Term, the Royalty Amount shall be payable only on Net Sales of Licensed Products which are covered by the claims of a Patent which has issued in the jurisdiction of the sale. If on or after January 1, 2004, a Licensed Product sold by Licensee is covered by the claims of an issued Patent in the jurisdiction of the sale, the Royalty Amount shall be calculated the same way as set forth in the preceding grammatical paragraph. However, if on or after January 1, 2004, a Licensed Product is not covered by an issued Patent in the jurisdiction of the sale, then no Royalty Amount shall be owed on the sale or distribution of such Licensed Product. This License Agreement shall remain in effect during the pendency of any patent applications (even though no Royalty Amounts may be due). If Licensor determines, after January 1, 2004, that no Patents covering the Licensed Products sold by Licensee will ever issue, then the Agreement shall terminate, and Licensee shall have no Royalty Amount obligations to Licensor, or other restrictions, respecting the Licensed Products sold or distributed after January 1, 2004. In other words, between April 1, 2001 and December 31, 2003, Licensor's entitlement to the Royalty Amount is in compensation for giving \u2587\u2587\u2587\u2587\u2587\u2587 a \"first mover\" advantage. However, on and after January 1, 2004, Licensor shall be entitled to a Royalty Amount only if that advantage has been made exclusive and sustainable by the issuance of a Patent covering Licensee's golf balls in the jurisdiction of sale of such Licensed Product.", "hash": "a3c26e8f1c56551bb61a800d4caf64cc", "id": 6}, {"snippet_links": [{"key": "to-the-seller", "type": "definition", "offset": [25, 38]}, {"key": "royalty-agreement", "type": "definition", "offset": [55, 72]}], "size": 1, "samples": [{"hash": "iDyfVrA9XO0", "uri": "/contracts/iDyfVrA9XO0#royalty-amount", "label": "Purchase and Sale Agreement (Caprius Inc)", "score": 18.0, "published": true}], "snippet": "means the amount payable to the Seller pursuant to the Royalty Agreement.", "hash": "5d9e35675b1e8d89e331e16499cc41a9", "id": 7}, {"snippet_links": [{"key": "equal-to", "type": "definition", "offset": [16, 24]}, {"key": "net-sales", "type": "definition", "offset": [31, 40]}, {"key": "by-the-acquiror", "type": "clause", "offset": [48, 63]}, {"key": "period-from", "type": "definition", "offset": [121, 132]}, {"key": "sale-of", "type": "clause", "offset": [137, 144]}, {"key": "for-purposes", "type": "definition", "offset": [154, 166]}], "size": 1, "samples": [{"hash": "iWvVzFHiWdr", "uri": "/contracts/iWvVzFHiWdr#royalty-amount", "label": "Asset Purchase Agreement (Kv Pharmaceutical Co /De/)", "score": 17.1033535004, "published": true}], "snippet": "means an amount equal to 5% of Net Sales booked by the Acquiror and any Affiliates of the Acquiror during the applicable period from the sale of Gestiva. For purposes", "hash": "dadeb18f5fa5913a02aa6def85bf9926", "id": 8}, {"snippet_links": [{"key": "the-value", "type": "clause", "offset": [12, 21]}, {"key": "costs-of-removal", "type": "clause", "offset": [110, 126]}, {"key": "expenses-of", "type": "clause", "offset": [203, 214]}], "size": 1, "samples": [{"hash": "5IiM5aUmz9K", "uri": "https://www.sec.gov/Archives/edgar/data/1164704/000100201402000022/exh102.htm", "label": "Alberta Exploration Co", "score": 5.0, "published": false}], "snippet": "means 2% of the Value of the Diamonds without any deduction whatsoever for the direct, indirect or incidental costs of removal or recovery other than mineral and mining taxes, royalties and the fees and expenses of Graders;", "hash": "973d26b9427d7ec90847bc4d5af96543", "id": 9}, {"snippet_links": [{"key": "equal-to", "type": "definition", "offset": [17, 25]}, {"key": "net-sales-price", "type": "clause", "offset": [37, 52]}, {"key": "products-sold", "type": "clause", "offset": [66, 79]}, {"key": "during-the-period", "type": "clause", "offset": [197, 214]}, {"key": "effective-date-of-this-agreement", "type": "clause", "offset": [233, 265]}, {"key": "day-of", "type": "clause", "offset": [289, 295]}, {"key": "full-calendar-month", "type": "definition", "offset": [321, 340]}, {"key": "royalty-period", "type": "definition", "offset": [358, 372]}], "size": 1, "samples": [{"hash": "2tmd53B2u9l", "uri": "/contracts/2tmd53B2u9l#royalty-amount", "label": "Royalty Agreement (Dexterity Surgical Inc)", "score": 18.0, "published": true}], "snippet": "means the amount equal to 15% of the Net Sales Price of Dexterity Products sold by LifeQuest, or any of its Affiliates or any Licensee, assignee or successor of LifeQuest or any of its Affiliates, during the period commencing on the effective date of this Agreement and ending on the last day of the eighty-fourth (84th) full calendar month thereafter (the \"Royalty Period\").", "hash": "5680e24ed6d9950e96e7fcda34c08423", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXcm95YWx0eS1hbW91bnQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 37, "snippet": "means the absolute dollar amount that VAR agrees to pay Versant each time the Application is distributed and recognized as revenue on VAR's income statement in accordance with Generally Accepted Accounting Principles, as set forth in Exhibit D hereto.", "title": "Royalty Amount", "id": "royalty-amount", "examples": ["The Initial <strong>Royalty Amount</strong> shall be reset to zero at the beginning of the second Contract Year.", "During the Exclusive Period, on or before each [***] following the Effective Date, Licensee will pay to the University the Minimum <strong>Royalty Amount</strong> (\u201cMRA\u201d) as specified in the Principal Terms &amp; Milestones List for the indicated MRA Year, wherein MRA Year 0 begins on the [***] following the Effective Date, MRA Year 1 begins on the second [***] following the Effective Date, etc.", "Notwithstanding the foregoing, the Running <strong>Royalty Amount</strong> otherwise due University may never be less than [***].", "Only one payment of Earned Royalty shall be due with respect to any Net Sales or only one payment of Earned <strong>Royalty Amount</strong> shall be due with respect to any Unit of CHIRON Licensed Product Shipped, irrespective of the number of patents or Valid Claims in the CHIRON Licensed Patents covering such CHIRON Licensed Product.", "Royalties paid to PalmSource for sales by Wholly Owned Subsidiaries will count toward Licensee\u2019s Minimum Annual Payment and Initial <strong>Royalty Amount</strong> in Exhibit D (Licensee Products, Royalties and Fees) in the same manner as Royalties paid for sales by Licensee.", "The power of attorney granted hereby is coupled with an interest, and may not be revoked or canceled by Seller without Purchaser\u2019s written consent; provided, however that the term of the foregoing power of attorney shall be effective from the Closing Date and shall terminate upon Purchaser\u2019s receipt of the Capped <strong>Royalty Amount</strong>.", "In the event that Licensee is required to pay Third Party Royalties, then Licensee may deduct an amount equal to [***] of any Third Party Royalties actually paid by Licensee from any Running <strong>Royalty Amount</strong> due University hereunder, [***] of the Running <strong>Royalty Amount</strong> otherwise owing under Section 4.01(D)(i) if and only if: [***].", "The Maintenance Fee applicable to copies of Run Time Software in addition to those listed above will be equal to [ * ] percent ([ * ]) of the <strong>Royalty Amount</strong> payable to Versant under this Agreement.", "No adjustment shall be made to any Earned <strong>Royalty Amount</strong> unless mutually agreed; [**].", "However, the Minimum <strong>Royalty Amount</strong> shall be reduced on a dollar-for-dollar basis by the amount excluded from the Royalty Payments to Westar as a result of the exclusion of the unit\u2019s sale price from the calculation of Goldfinger Product Sales for purposes of making such Royalty Payments."], "related": [["royalty-payments", "Royalty Payments", "Royalty Payments"], ["net-sales-revenue", "Net Sales Revenue", "Net Sales Revenue"], ["royalty-payment", "Royalty Payment", "Royalty Payment"], ["minimum-royalty", "Minimum Royalty", "Minimum Royalty"], ["gross-sales-price", "Gross Sales Price", "Gross Sales Price"]], "related_snippets": [], "updated": "2026-03-14T06:33:37+00:00"}, "json": true, "cursor": ""}}